详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Drug-Loaded Biomimetic Carriers for Non-Hodgkin's Lymphoma Therapy: Advances and Perspective

9| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Shandong Second Med Univ, Sch Clin Med, Weifang 261000, Shandong, Peoples R China [2]Linyi Peoples Hosp, Cent Lab, Linyi 276000, Shandong, Peoples R China [3]Linyi Key Lab Nanomed, Linyi 276000, Shandong, Peoples R China [4]Linyi Peoples Hosp, Dept Hematol, Linyi 276000, Shandong, Peoples R China [5]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310000, Zhejiang, Peoples R China [6]First Affiliated Hosp, Sch Med, Key Lab Combined Multiorgan Transplantat, Minist Publ Hlth, Hangzhou 310000, Zhejiang, Peoples R China [7]Guangzhou Univ Chinese Med, Guangzhou 510000, Guangdong, Peoples R China [8]Linyi Key Lab Tumor Biol, Linyi 276000, Shandong, Peoples R China [9]Xuzhou Med Univ, Key Lab Translat Oncol, Xuzhou 221000, Jiangsu, Peoples R China

出处：

DOI：

ISSN：

关键词： non-Hodgkin's lymphoma drug-loaded biomimeticcarriers therapy

摘要：

Chemotherapy remains the mainstay of treatment for the lymphoma patient population, despite its relatively poor therapeutic results, high toxicity, and low specificity. With the advancement of biotechnology, the significance of drug-loading biomimetic materials in the medical field has become increasingly evident, attracting extensive attention from the scientific community and the pharmaceutical industry. Given that they can cater to the particular requirements of lymphoma patients, drug-loading biomimetic materials have recently become a potent and promising delivery approach for various applications. This review mainly reviews the recent advancements in the treatment of tumors with biological drug carrier-loaded drugs, outlines the mechanisms of lymphoma development and the diverse treatment modalities currently available, and discusses the merits and limitations of biological drug carriers. What is more, the practical application of biocarriers in tumors is explored by providing examples, and the possibility of loading such organisms with antilymphoma drugs for the treatment of lymphoma is conceived.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 3 区材料科学：生物材料

最新[2025]版：

大类 | 3 区医学

小类 | 3 区材料科学：生物材料

JCR分区：

出版当年[2022]版：

Q2 MATERIALS SCIENCE, BIOMATERIALS

最新[2023]版：

Q2 MATERIALS SCIENCE, BIOMATERIALS

影响因子： 5.5 最新[2023版] 5.5 最新五年平均 5.7 出版当年[2022版] 5.6 出版当年五年平均 5.395 出版前一年[2021版] 5.5 出版后一年[2023版]

第一作者：

第一作者机构： [1]Shandong Second Med Univ, Sch Clin Med, Weifang 261000, Shandong, Peoples R China [2]Linyi Peoples Hosp, Cent Lab, Linyi 276000, Shandong, Peoples R China [3]Linyi Key Lab Nanomed, Linyi 276000, Shandong, Peoples R China

共同第一作者：

通讯作者：

通讯机构： [2]Linyi Peoples Hosp, Cent Lab, Linyi 276000, Shandong, Peoples R China [3]Linyi Key Lab Nanomed, Linyi 276000, Shandong, Peoples R China [8]Linyi Key Lab Tumor Biol, Linyi 276000, Shandong, Peoples R China [9]Xuzhou Med Univ, Key Lab Translat Oncol, Xuzhou 221000, Jiangsu, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type. [2]Concomitant non-Hodgkin's lymphoma in colon and liver: report of a rare case and review of literature [3]Concomitant non-Hodgkin's lymphoma in colon and liver: Report of a rare case and review of literature [4]Sonodynamic therapy-derived multimodal synergistic cancer therapy. [5]Early goal-directed therapy is not equivalent to goal-oriented therapy or protocol-directed therapy [6]Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer [7]High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients after planned extubation. [8]Iron oxide-EDTA nanoparticles for chelation-enhanced chemodynamic therapy and ion interference therapy [9]Multifunctional Magnetic Nanoagents for Bioimaging and Therapy [10]Role of Exosomes in Photodynamic Anticancer Therapy.